A Phase 4 interventional study of First dose rimegepant, second dose placebo and First dose placebo, second dose rimegepant in Vestibular Migraine, sponsored by Wensheng Qu. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Wensheng Qu · Phase 4, Interventional, and Treatment
Among 78 studies in Migraine Disorders with a site in China — 32 open to participants now, 39 under way, 10 of them phase 3. Migraine Disorders · China.
Among the 78 studies in Migraine Disorders with a site in China, this one is the 48th largest by planned enrollment of the 59 interventional ones, is one of 13 that started in 2025, is one of 6 in phase 4, reaches primary completion later than 26 of the 38 other live ones, and was the 69th registered.
1,657 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.
This study's planned enrollment of 80 is close to the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Browse Migraine Disorders studies →32 of the 78 studies in Migraine Disorders with a site in China are open now, in 12 countries. Each count lists the studies.
Of the 216 Migraine Disorders studies recruiting now, 65 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →78 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 13 started in 2025.
Median enrollment 260 across the 59 interventional studies, 330 across the 19 observational. Of the 28 that completed or were terminated, 10 (36%) have results posted.
22 of 78 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Wensheng Qu as lead sponsor.
Wensheng Qu has 1 study filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
9 of the studies in Migraine Disorders with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07347028Beijing Tiantan HospitalClinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Knee Osteoarthritis(OA) | 2026-12-01 |
| NCT07347067Beijing Tiantan HospitalClinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Migraine | 2026-12-01 |
| NCT06347276China National Center for Cardiovascular DiseasesCerebral Microembolization Associated With PFO Closure | 2026-12-31 |
| NCT06953622Peking University Third HospitalEstablishment of a Clinical and Prognostic Follow-up Cohort of Migraine Patients With Patent Foramen Ovale | 2026-12-31 |
Among the 78 studies in Migraine Disorders with a site in China, from their registry updates:
To evaluate whether rimegepant improves acute vestibular symptoms and accompanying discomforts in patients with vestibular migraine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
First dose rimegepant, second dose placebo
Drug: First dose rimegepant, second dose placebo · Drug: First dose placebo, second dose rimegepant
First dose placebo, second dose rimegepant
Drug: First dose rimegepant, second dose placebo · Drug: First dose placebo, second dose rimegepant
First dose rimegepant, second dose placebo
First dose placebo, second dose rimegepant
Vertigo symptom relief rate
After 2 hours of medication, vertigo symptoms improved from moderate or severe to mild or no vertigo.
Time frame: 2 hours after medication
headache relief rate
After 2 hours of medication, headache symptoms improved from moderate or severe to mild or no vertigo
Time frame: 2 hours after medication
relief rate of nausea and vomiting
After 2 hours of medication, complete resolution rate of nausea and vomiting
Time frame: 2 hours after medication
relief rate of photophobia and phonophobia
After 2 hours of medication, complete resolution rate of photophobia and phonophobia
Time frame: 2 hours after medication
daily activities
Time to resume normal daily activities
Time frame: day 1 after medication
Rescue medication
Use rate of rescue medication
Time frame: within the first day after medication
relief rate of vertigo symptoms
After 2 hours of medication, complete resolution rate of vertigo symptoms
Time frame: 2 hours after medication
Plan to share: Yes — De-identified individual participant data will be shared, including demographic characteristics (e.g., age and sex), baseline clinical characteristics, migraine-related efficacy outcomes (e.g., migraine frequency, pain freedom, and symptom relief), and safety data (e.g., adverse events and laboratory results). The final analyzable dataset used for statistical analyses will also be provided.
Supporting information: Study protocol
Time frame: 6 months after publication of the primary results 5 years after publication of the primary results
Access criteria: Qualified researchers with a scientifically sound research proposal will be eligible to access the data. Available data will include de-identified individual participant data (IPD), the final analyzable dataset, and supporting documents such as the study protocol and statistical analysis plan. Access will be granted upon reasonable request and subject to review and approval by the study investigators. Data will be shared under a data use agreement to ensure the protection of participant confidentiality and compliance with applicable regulations. Requests should be submitted to the corresponding investigator via institutional email.
Data sharing details ↗ · example.com
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Nov 2027, 23 months after the start.
Of 49 non-industry phase 4 interventional studies under Migraine Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 51. This study's planned 23 months is below that.
Counting every sponsor, half of 77 studies reached it within 27 months; a quarter within 17 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.